Abstract 547P
Background
Immunotherapy is now standard of care in advanced/metastatic lung cancer patients either in first line alone or in combination with chemotherapy, also in subsequent lines. Here, we presenting real world outcome with immunotherapy in lung cancer patients from India.
Methods
We performed an analysis of prospectively collected data of patients with advanced/metastatic lung cancer treated at a single academic cancer centre in India. The patient’s demographic data, treatment details, toxicity and response to treatment captured from electronic medical record of each patient. Data was analysed for safety and survival outcome.
Results
From August 2015 to September 2021, 164 eligible patients were included in this study. Median age at presentation was 59 year (range 21 year to 86 year). 82% (n=134) were male and 18% (n=34) were female (M: F 4.5:1). At presentation, 73% (n=118) were ECOG PS 0 or 1, 14.5% (n=24) were ECOG PS 2, and 12.5% (n=22) were ECOG PS 3 or 4. Out of 164, 33% (n = 54), received immunotherapy drug in first line, 46% (n = 76) in second line, 21% (n = 34) in third line and beyond. 65% (n=106) received Nivolumab, 26.5% (n=44) received Pembrolizumab, 8.5% (n=14) received Atezolizumab. Median progression free survival and median overall survival was 5 months (95% CI 3.5 to 6.5 month) and 10 months (95% CI 7.3 to 12.7 month) respectively. Overall, 3-year PFS and OS rate is 5% and 23%. Fatigue was most common seen in 15% patients, hyponatremia in 5.3%, anorexia in 2.4%. Among immune-related toxicity- pneumonitis was most common seen in 4.8%, followed by hypothyroidism in 3.8%, transaminitis and nephritis in 1.9% each, skin rash, colitis, and encephalitis in 1.4% each, adrenal insufficiency and hypophysitis in 1% each seen.
Conclusions
In real world, immunotherapy having clinically significant benefit on survival in advanced/metastatic lung cancer patients with acceptable safety profile including patients with borderline performance status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract